Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04619433

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.

Clinical Trial Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.

Clinical Trial Description

The study is being conducted to evaluate the efficacy and safety of Camrelizumab in combination with Famitinib plus chemotherapy in subjects with NSCLC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04619433
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Recruiting
Phase Phase 3
Start date February 1, 2021
Completion date October 15, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04504916 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002) Phase 2
Not yet recruiting NCT05849246 - The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Phase 2
Active, not recruiting NCT04396457 - Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 Phase 2
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Terminated NCT04265534 - KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Phase 2
Active, not recruiting NCT05258279 - Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations Phase 2
Not yet recruiting NCT04453423 - Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. Phase 2
Terminated NCT04173338 - Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Phase 1
Terminated NCT04698681 - NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
Active, not recruiting NCT04211090 - Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC Phase 2
Recruiting NCT04084717 - Study of Crizotinib for ROS1 and MET Activated Lung Cancer Phase 2
Recruiting NCT04958811 - Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC Phase 2
Completed NCT00152477 - A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer Phase 2
Completed NCT04012619 - Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer Phase 1
Recruiting NCT05403554 - A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers Phase 1
Completed NCT05318443 - A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer Phase 3